The switch in question is a chemically modified version of a transcription factor called KLF5, or Krüppel-like factor 5. In earlier work, the same group showed that transforming growth factor beta, or TGF-β, a signaling molecule abundant in the bone microenvironment, induces the addition of an acetyl group to KLF5 at a specific position, lysine 369. This acetylated form of KLF5, abbreviated Ac-KLF5, acts as a master regulator of malignancy: it drives epithelial-mesenchymal transition, the process by which cancer cells shed their adhesive character and become invasive, and it promotes the osteolytic destruction of bone that characterizes metastatic lesions. Because Ac-KLF5 sits at the convergence of bone-derived signals and metastatic behavior, the researchers reasoned that it, and the genes it controls, would make an ideal therapeutic target.

Finding a drug that disables a transcription factor is notoriously difficult, since these proteins lack the deep pockets that small molecules typically exploit. The team therefore turned to an unbiased, systematic approach. Using surface plasmon resonance, a label-free biophysical technique that measures binding in real time, they screened a library of 1,987 FDA-approved compounds against a purified mimic of acetylated KLF5, a mutant in which lysine 369 is replaced by glutamine, known as KQ. This substitution mimics the charge and structural consequences of acetylation, allowing the researchers to fish for molecules that recognize the acetylated state specifically.

The screen produced a clear and surprising winner: the tetracycline family of antibiotics. Doxycycline and methacycline both bound selectively to the KQ protein, but crucially, they showed no detectable binding to an acetylation-deficient mutant, KLF5 K369R, in which lysine is replaced by arginine. The parent compound, tetracycline itself, failed to bind either protein. The selectivity was verified not only by surface plasmon resonance but also by circular dichroism spectroscopy, which tracks changes in protein secondary structure upon ligand binding. In other words, the anti-metastatic potential of these old antibiotics appears to hinge on a chemical modification of KLF5 that ordinary tetracycline cannot recognize.

Binding alone proves nothing unless it changes cell behavior, so the team moved to functional assays. In prostate cancer cells engineered to express the acetylation-mimicking KQ mutant, doxycycline and methacycline significantly inhibited invasion in three-dimensional spheroid invasion assays and Transwell migration assays, while tetracycline again had no effect. The drugs also suppressed the ability of cancer cells to promote osteoclast differentiation, the process by which bone-resorbing cells are recruited and activated in metastatic lesions. These results established that the physical interaction between the antibiotics and acetylated KLF5 translates directly into reduced metastatic behavior in vitro.

To test therapeutic efficacy in a living system, the researchers used tibial injection xenograft models, in which human prostate cancer cells are introduced directly into the mouse tibia, recreating the osteolytic bone metastasis that plagues patients. Tumors were tracked with bioluminescence imaging, bone destruction was quantified by micro-computed tomography, and lesions were examined histologically. Doxycycline and methacycline treatment markedly reduced tumor burden and osteolytic damage in this setting, whereas tetracycline again failed to help. The in vivo data, generated under approved animal ethics protocols at the Shenzhen institution, provided the strongest evidence yet that targeting Ac-KLF5 can blunt bone metastasis in a whole organism.

The mechanistic core of the study came from integrating two genome-wide datasets. RNA sequencing revealed which genes change their expression when the drugs are applied, while chromatin immunoprecipitation sequencing, or ChIP-seq, mapped where acetylated KLF5 binds directly to gene promoters. The overlap yielded 22 genes whose transcription is regulated both by KQ through direct promoter binding and by doxycycline and methacycline treatment, identifying a compact drug-sensitive transcriptional program downstream of Ac-KLF5. Quantitative PCR, small interfering RNA knockdown, and rescue experiments validated these connections.

Among the 22 genes, one stood out: PGK1, which encodes phosphoglycerate kinase 1, a glycolytic enzyme best known for its role in energy metabolism but increasingly recognized as a contributor to cancer progression. Follow-up experiments confirmed that PGK1 is responsible for the suppressive effects of doxycycline and methacycline on cell invasion, osteoclast differentiation, and bone metastasis. The finding ties metastatic aggression to metabolic rewiring and suggests that acetylated KLF5 acts partly by elevating a glycolytic enzyme that fuels invasive behavior and supports the bone-destroying cycle of metastasis.

The clinical implications are considerable. Doxycycline is cheap, orally available, and carries decades of safety data from its use as an antibiotic and anti-inflammatory agent, which means a repurposing pathway could move faster than de novo drug development. The study also resolves a long-standing puzzle: tetracycline derivatives were known to show anti-metastatic activity, but their molecular targets had remained unidentified, limiting rational clinical use. By pinning that activity to selective binding of acetylated KLF5 and its control of PGK1, the researchers have converted an empirical observation into a targetable mechanism, and their screening strategy offers a template for finding inhibitors of other acetylated transcription factors.

Cautions remain before patients benefit. The work relied on cell models and mouse xenografts rather than human trials, and the drug concentrations and schedules used experimentally may not map directly onto clinical dosing. Castration-resistant and metastatic castration-resistant prostate cancer are treated today with docetaxel and androgen-targeting agents, and any antibiotic-based regimen would need to demonstrate added benefit in combination or as maintenance therapy. Nonetheless, the identification of acetylated KLF5 as a druggable node in TGF-β-driven bone metastasis, published open access in BMC Medicine by Duo Zhang, Xinyuan Jiang, Yutian Ren and colleagues under the correspondence of Jin-Tang Dong, gives researchers a concrete molecular bullseye in one of oncology’s most lethal scenarios, and it suggests that a fifty-year-old antibiotic may yet have a role to play in keeping prostate cancer out of the bone.

Subject of Research: Targeting acetylated KLF5 with tetracycline antibiotics to inhibit prostate cancer bone metastasis

Article Title: Acetylated KLF5 as a therapeutic target mediating the anti-metastatic effects of doxycycline and methacycline in prostate cancer bone metastasis

Article References: Zhang, D., Jiang, X., Ren, Y., Qin, Y., Lin, X., Deng, S., Zhou, Q., Chen, Y., Zhang, Z., Zhang, X., & Dong, J.-T. (2026). Acetylated KLF5 as a therapeutic target mediating the anti-metastatic effects of doxycycline and methacycline in prostate cancer bone metastasis. BMC Medicine. https://doi.org/10.1186/s12916-026-05190-3

Image Credits: AI Generated

DOI: 10.1186/s12916-026-05190-3

Keywords: acetylated KLF5, prostate cancer, bone metastasis, doxycycline, methacycline, tetracycline derivatives, TGF-beta, drug repurposing, PGK1, epithelial-mesenchymal transition, osteoclast differentiation, BMC Medicine

The investigation began with a rigorous bioinformatic sweep of publicly available genomic data. The researchers mined The Cancer Genome Atlas HNSC dataset alongside four independent Gene Expression Omnibus datasets, namely GSE127165, GSE10121, GSE37991, and GSE30784, to identify genes consistently upregulated in tumor tissues compared with adjacent normal tissues. This cross-cohort analysis flagged 311 genes elevated in HNSCC, and among them, CCT2 stood out. Subsequent univariate Cox regression analysis across the GSE41613 and GSE42743 datasets narrowed the field to 45 common prognosis-associated genes, and CCT2 again emerged as a standout signal. Across all datasets examined, high CCT2 expression predicted poor prognosis, advanced clinical stage, and more aggressive tumor characteristics, painting a consistent statistical portrait of a gene that tracks with the worst outcomes in this disease.

Bioinformatics alone, however, can only suggest; the team turned to human tissue and laboratory models to confirm the biology. Immunohistochemistry performed on patient samples revealed robust CCT2 staining in tumor tissue relative to normal epithelium, and the same sections showed elevated Ki-67, a canonical marker of cellular proliferation, hinting that CCT2-expressing tumors were actively dividing. Western blotting on paired tumor and adjacent normal tissues from patient samples confirmed the protein-level overexpression, and the pattern held in cell culture: HNSCC cell lines including HSC-3, CAL-27, and SAS expressed far more CCT2 than normal epithelial cell lines such as HOEC and HIEC6. With the overexpression established at the transcript, protein, and tissue levels, the researchers moved to the critical question of causation.

The answer came from loss-of-function experiments that were strikingly decisive. When the researchers depleted CCT2 using knockdown techniques, HNSCC cells lost their ability to proliferate efficiently in vitro, and tumor growth slowed in vivo as well. Beyond proliferation, CCT2 depletion crippled the migratory and invasive capacities of the cancer cells, the very behaviors that enable metastasis and account for much of the lethality of head and neck cancer. Molecular profiling of these changes revealed a classic shift in epithelial-mesenchymal transition markers: the epithelial adhesion molecule E-cadherin increased, while the mesenchymal markers N-cadherin, vimentin, and Slug decreased. This signature indicates that CCT2 normally pushes cells toward the motile, invasive mesenchymal state, and its removal reverses that program, effectively locking tumor cells into a less aggressive identity.

Perhaps the most clinically consequential finding concerned cisplatin, the platinum-based chemotherapy that remains the backbone of treatment for advanced HNSCC despite frequent resistance. The researchers observed a positive correlation between CCT2 expression and cisplatin IC50 values across HNSCC cell lines, meaning that cells with more CCT2 required higher doses of the drug to die. When CCT2 was knocked down, cisplatin sensitivity rose both in cultured cells and in living tumor models, demonstrating that the effect is not an artifact of cell culture. This result positions CCT2 as a cell-intrinsic mediator of chemoresistance, offering a mechanistic explanation for why some head and neck tumors shrug off a drug that should, in principle, destroy them.

To understand how a protein chaperone subunit could exert such sweeping influence, the team dug into the signaling pathways enriched in CCT2-high tumors and found a strong signature of MYC-related activity. Co-immunoprecipitation experiments then demonstrated a direct physical interaction between CCT2 and c-Myc, the infamous transcription factor and oncogenic driver whose overexpression fuels growth in a wide range of cancers. The interaction proved functionally meaningful: cycloheximide-chase experiments, which track protein decay over time after blocking new protein synthesis, showed that CCT2 knockdown reduced c-Myc stability and shortened its half-life. In other words, CCT2 acts as a molecular bodyguard for c-Myc, protecting the oncoprotein from degradation and allowing it to accumulate to pathological levels inside tumor cells.

Downstream of this stabilization, CCT2’s influence on the cell cycle became apparent. The researchers found that CCT2 affected key cell-cycle regulators, including cyclin D1, encoded by CCND1, and cyclin E1, encoded by CCNE1, both of which drive the transitions that propel cells through division. To establish c-Myc as the functional mediator of CCT2’s effects, the team performed rescue experiments: when they overexpressed c-Myc in CCT2-deficient cells, cell-cycle progression was restored and the impaired migration and invasion were partially rescued. Conversely, knocking down c-Myc increased cisplatin sensitivity, mirroring the effect of CCT2 depletion itself. Together, these experiments sketch a coherent pathway in which CCT2 stabilizes c-Myc, which in turn orchestrates the cell-cycle programs and aggressive behaviors that define advanced HNSCC.

The study then uncovered an even more unsettling dimension of CCT2 biology, one that extends beyond individual cells to entire tumor populations. The researchers identified apoptotic vesicles, or apoVs, as vehicles for transferring chemoresistance between neighboring tumor cells. ApoVs released from cisplatin-treated HNSCC cells were found to contain CCT2, and recipient tumor cells internalized these vesicles. Once inside, the CCT2 cargo raised both CCT2 and c-Myc levels in the recipient cells, altered their cell-cycle regulators, accelerated their cell-cycle progression, and enhanced their resistance to cisplatin. Critically, vesicles derived from CCT2-depleted cells showed much weaker effects, confirming that the CCT2 payload itself was responsible for transmitting drug tolerance. This mechanism represents a form of non-genetic transfer of resistance, meaning that chemotherapy itself may inadvertently arm previously sensitive cells with the molecular machinery of survival, without any DNA mutation required.

Taken together, the findings reframe CCT2 from an obscure chaperonin subunit into a central node in the biology of head and neck squamous cell carcinoma. The protein promotes proliferation, migration, and invasion while simultaneously reducing cisplatin sensitivity through its interaction with and stabilization of c-Myc, and the apoptotic vesicle pathway adds a population-level mechanism by which resistance spreads through the tumor. For clinicians, the work suggests that CCT2 expression could serve as a biomarker for identifying patients whose tumors are likely to resist cisplatin, potentially guiding treatment intensification or alternative regimens. For drug developers, CCT2 presents an attractive therapeutic target, particularly because its effects appear to converge on a single, druggable axis involving c-Myc stabilization. As head and neck cancer continues to exact a devastating toll worldwide, strategies that disrupt the CCT2-c-Myc partnership, or that intercept the vesicle-mediated trafficking of resistance between tumor cells, could finally offer a way to blunt the rapid progression and treatment failure that have long characterized this aggressive malignancy.

Subject of Research: The role of the chaperonin subunit CCT2 in stabilizing c-Myc to drive progression and cisplatin chemoresistance in head and neck squamous cell carcinoma

Article Title: CCT2 drives HNSCC progression and cisplatin chemoresistance

Article References: CCT2 drives HNSCC progression and cisplatin chemoresistance. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: head and neck squamous cell carcinoma, CCT2, chaperonin-containing TCP-1 complex, c-Myc, cisplatin resistance, chemoresistance, epithelial-mesenchymal transition, apoptotic vesicles, cell cycle, CCND1, CCNE1, Genes & Diseases

Cellular senescence is a state in which cells stop dividing permanently, usually in response to stress such as DNA damage, telomere shortening, or oxidative injury. Senescent cells are not simply dormant; they often develop what researchers call the senescence-associated secretory phenotype, a program in which they release a cocktail of inflammatory cytokines, growth factors, and enzymes that degrade the extracellular matrix. In many cancers, this secretory output is thought to create a pro-tumorigenic niche. Yet the precise contribution of senescent fibroblasts in ovarian cancer, and the identity of the molecules they use to communicate with tumor cells, had remained poorly defined. The new work set out to close that gap by combining large-scale genomic data with laboratory experiments and clinical samples.

The researchers began by mining publicly available single-cell RNA sequencing datasets, which measure gene expression in thousands of individual cells, alongside spatial transcriptomic data that preserve information about where cells sit within the tumor architecture. They also analyzed clinical specimens obtained from patients at Nanfang Hospital, with ethics approval and informed consent. By applying gene signatures associated with senescence to the fibroblast populations identified in these data, the team showed that cancer-associated fibroblasts in high-grade serous ovarian cancer carry a markedly elevated senescence program compared with other stromal and immune cell types in the same tumors. Spatial analysis placed these senescent fibroblasts in close proximity to malignant epithelial cells, hinting at a functional dialogue between the two compartments.

To translate that observation into something clinically useful, the team built a prognostic model based on the transcriptomic signature of the senescent fibroblasts. They used least absolute shrinkage and selection operator regression, a machine-learning technique that selects a compact set of predictive genes from a much larger candidate list, to derive a risk score for individual patients. When applied to cohort data, a high score on this senescent-fibroblast signature predicted significantly worse overall survival. The model therefore offers a way to stratify patients at diagnosis, potentially identifying those whose tumors are being nurtured by an aged stromal microenvironment and who might benefit from more aggressive or targeted treatment strategies.

The next question was mechanistic: which molecule, or molecules, do senescent fibroblasts use to promote tumor growth? Cell-cell communication analysis, a computational approach that matches ligands expressed by one cell type with receptors expressed by another, flagged Tenascin-C as a leading candidate. Tenascin-C is a large glycoprotein of the extracellular matrix that is abundant in embryonic tissues, largely absent from healthy adult tissue, and re-expressed in wounds and tumors. Among the genes in the prognostic signature, Tenascin-C stood out as a secreted effector produced by senescent fibroblasts and capable of signaling directly to tumor cells, making it an attractive linchpin for the observed pro-tumor effect.

Functional experiments in cell culture and in animal models confirmed the suspicion. When tumor cells were exposed to conditioned medium from senescent cancer-associated fibroblasts, they became more invasive and more migratory, hallmarks of malignant progression. Depleting or blocking Tenascin-C blunted these effects, demonstrating that the protein is a necessary mediator rather than a bystander. In vivo, the presence of senescent fibroblasts accelerated tumor growth in mouse models, and interference with the Tenascin-C axis reduced that acceleration. Together, these assays moved the finding from correlation to causation: the aged stromal cells promote ovarian cancer progression, and they do so substantially through Tenascin-C.

The study also resolved the signaling logic on both sides of the communication. On the receiving end, Tenascin-C engages syndecan-4, a transmembrane proteoglycan on the surface of tumor cells, which triggers the ERK mitogen-activated protein kinase pathway. ERK activation, in turn, drives epithelial-mesenchymal transition, a developmental program that cancer cells co-opt to lose their adhesive, epithelial character and acquire the motile, invasive traits of mesenchymal cells. Epithelial-mesenchymal transition is a well-established engine of metastasis and treatment resistance, so its induction explains how Tenascin-C exposure translates into poorer clinical outcomes. On the sending end, the researchers found that the nuclear factor kappa B pathway, a central inflammatory signaling cascade, is activated in the senescent fibroblasts and transcriptionally upregulates Tenascin-C expression, linking the senescence program itself to the production of the tumor-promoting factor.

To test how general the phenomenon might be, the team performed a pan-cancer analysis, examining the senescent-fibroblast risk score and Tenascin-C expression across multiple tumor types. The pattern held: high expression of Tenascin-C and a high senescent-fibroblast risk score were associated with worse overall survival across a range of solid tumors, not just ovarian cancer. This breadth suggests that the senescent stromal niche is not a peculiarity of high-grade serous ovarian cancer but a recurring feature of the tumor microenvironment, and that Tenascin-C may represent a broadly relevant node at which aged stroma communicates malignancy to neighboring epithelial cells.

The therapeutic implications are significant. High-grade serous ovarian cancer is typically diagnosed at an advanced stage and, despite initial responses to surgery and platinum-based chemotherapy, frequently recurs and eventually becomes resistant to treatment. Agents that target the tumor microenvironment rather than the tumor cells alone have shown promise in other contexts, and the identification of a single, druggable secreted mediator offers a concrete strategy. Blocking Tenascin-C, interrupting its binding to syndecan-4, or dampening the NF-kappaB-driven secretory program in senescent fibroblasts could, in principle, starve tumors of a key progression signal. Approaches that eliminate senescent cells altogether, so-called senolytics, represent another avenue suggested by this work, though the authors’ data point most directly at the Tenascin-C pathway itself.

As with any study, caveats apply. The prognostic model was developed and evaluated on existing datasets and clinical specimens, and prospective validation in independent patient cohorts will be needed before it can inform clinical decision-making. The mechanistic experiments, while thorough, were conducted in cell culture and animal models, and the complexity of the human tumor microenvironment, with its immune, vascular, and matrix components, may modulate the Tenascin-C pathway in ways not fully captured in the laboratory. Nevertheless, the study delivers an unusually complete chain of evidence, from single-cell atlas to survival statistics to signaling biochemistry, and it reframes cellular senescence in cancer not merely as a marker of an aged microenvironment but as an active, targetable driver of tumor progression. For patients with high-grade serous ovarian cancer, whose options narrow sharply at recurrence, a new molecular handle on the stromal side of the disease is a development worth watching closely.

Subject of Research: Senescent cancer-associated fibroblasts secreting Tenascin-C to promote tumor progression in high-grade serous ovarian cancer

Article Title: Senescent cancer-associated fibroblasts secrete Tenascin-C to promote tumor progression in high-grade serous ovarian cancer

Article References: Li, R., Chen, Y., Huang, X., Cai, J., Yang, Y., Fan, H., Xiang, Y., Meng, F., Huang, L., Li, Y., & Ning, Y. (2026). Senescent cancer-associated fibroblasts secrete Tenascin-C to promote tumor progression in high-grade serous ovarian cancer. Genome Medicine. https://doi.org/10.1186/s13073-026-01795-8

Image Credits: AI Generated

DOI: 10.1186/s13073-026-01795-8

Keywords: ovarian cancer, cancer-associated fibroblasts, cellular senescence, Tenascin-C, tumor microenvironment, epithelial-mesenchymal transition, NF-kappaB, ERK signaling, single-cell RNA sequencing, prognostic model, high-grade serous ovarian cancer, senescence-associated secretory phenotype

The extracellular matrix, long dismissed as little more than biological mortar, has increasingly been recognized as an active participant in tumor biology. In colorectal cancer, the matrix is often remodeled and enriched with fibrillar collagens, creating a dense, stiff environment that can influence how cells sense their surroundings. The Nottingham-led team began by mining publicly available transcriptomic datasets from colorectal cancer patients, including GSE44861 and GSE32323, and found that collagen-associated genes, particularly COL1A1 and COL1A2, which encode the alpha chains of type I collagen, were consistently upregulated in tumors compared with healthy tissue. Immunofluorescence staining of patient tumors confirmed frequent accumulation of collagen I in the tumor microenvironment, and Kaplan-Meier survival analysis linked high collagen I signaling to poorer patient outcomes.

To interrogate these correlations experimentally, the researchers turned to patient-derived organoids, miniature three-dimensional tumor cultures grown from surgical biopsies obtained at Queen’s Medical Centre in Nottingham with ethical approval and patient consent. These organoids preserve the genetic and epigenetic identity of the original tumors, including canonical colorectal cancer alterations such as APC, KRAS and TP53 mutations, making them far more faithful than conventional cell lines. The team embedded organoids in a mixed Matrigel-collagen I matrix, designated MGCOL, and compared them with organoids grown in standard Matrigel alone. Two-photon microscopy using second harmonic generation allowed the researchers to visualize the collagen fibers directly within the living gels, while rheological measurements tracked the mechanical properties of the matrices over nearly a month of culture.

The results were unambiguous. When colorectal cancer organoids were grown in collagen I-enriched matrices, they mounted a robust activation of transforming growth factor beta signaling, a master pathway controlling tissue repair, cell identity and immune modulation. Alongside this, the cells increased their expression of LTBP2, latent transforming growth factor-beta binding protein 2, a secreted extracellular protein that sequesters and regulates TGFβ family ligands. The organoids also activated a partial epithelial-to-mesenchymal transition program, a transcriptional shift in which epithelial cells acquire mesenchymal traits such as motility, invasiveness and stress resistance, without fully abandoning their epithelial character. This partial EMT state is increasingly viewed as a hallmark of aggressive, treatment-refractory tumors.

Crucially, the researchers wanted to know whether these matrix-induced changes would persist once cells left the dish. They transplanted collagen I-primed organoids into xenograft mouse models and found that the resulting tumors retained an EMT-biased, LTBP2-high phenotype with elevated TGFβ pathway activation, as measured by phosphorylated SMAD2 staining. This persistence in vivo suggests that the extracellular matrix does not merely produce transient, reversible changes but can lock tumor cells into alternative identity states that survive transplantation. The finding carries significant implications, because it implies that the matrix composition of a patient’s tumor could pre-condition cancer cells before any drug is administered.

The clinical relevance of the LTBP2 signature was reinforced by analysis of The Cancer Genome Atlas colon adenocarcinoma cohort. LTBP2 expression was significantly elevated in metastatic colorectal cancer compared with primary tumors and healthy colon, and high LTBP2 expression was associated with worse disease-free survival across more than 1,300 patients, with a hazard ratio of 1.41. INHBA, another TGFβ pathway component induced by collagen I, showed an even stronger association, with a hazard ratio of 2.48. LTBP2 expression also correlated strongly with FBN1 and LOXL1, genes involved in elastic fiber assembly and collagen cross-linking, tying the LTBP2 signal directly to matrix remodeling biology.

Perhaps the most consequential discovery concerned chemotherapy. When the researchers treated collagen I-primed and control organoids with 5-fluorouracil, the standard backbone drug for colorectal cancer, the collagen-rich environment markedly enhanced the pro-inflammatory transcriptional response to the drug. Cells in collagen I-rich matrices responded to chemotherapy by ramping up inflammatory signaling programs, including chemokine expression, rather than simply undergoing cell death. Pharmacological inhibition of TGFβ signaling using the TGFβ receptor 1 inhibitor SB431542, or of p38 MAPK signaling using SB202190, modulated this chemotherapy-induced inflammatory program, implicating both pathways as mechanistic links between the matrix and the drug response. In other words, the same scaffold that primes cells toward plasticity also tunes how they react when attacked by cytotoxic therapy.

The authors propose that collagen I establishes a distinct tumor microenvironmental niche in which TGFβ-dependent EMT priming, epithelial plasticity and altered chemotherapy responses converge. Rather than a single driver mutation or a single signaling pathway, treatment resistance may emerge from the interplay between a tumor’s genetic identity and the physical and biochemical properties of its surroundings. This mechanistic framework helps explain why patients with histologically similar tumors can respond so differently to identical regimens, and it suggests that matrix composition, measurable through staining or imaging approaches such as Picrosirius red and second harmonic generation, could serve as a biomarker for treatment stratification.

The study also validates collagen I-enriched organoid cultures as a physiologically relevant platform for studying matrix-tumor interactions, something that standard Matrigel cultures, which lack the fibrillar collagen architecture of real tumors, cannot fully capture. By adjusting matrix composition in a controlled way, researchers can now dissect how individual matrix components shape cell state and drug sensitivity in patient-specific backgrounds. The work was supported by the Medical Research Council, the Royal Society and Research Foundation Flanders, and the authors note that the findings support further investigation of TGFβ and p38 signaling as potential therapeutic targets to overcome matrix-mediated treatment resistance.

For patients, the message is that the terrain around a tumor matters as much as the tumor itself. If collagen I-rich niches prime cancer cells to adapt and inflame rather than die under chemotherapy pressure, then combination strategies that target the matrix or its downstream signaling could sensitize tumors that would otherwise resist treatment. While the research remains at the preclinical stage, resting on organoid and xenograft models rather than clinical trials, it adds colorectal cancer to the growing list of malignancies in which the extracellular matrix is emerging as an active architect of therapeutic failure, and it hands clinicians and drug developers a concrete set of molecular handles, LTBP2, TGFβ and p38, with which to intervene.

Subject of Research: Collagen I-driven extracellular matrix regulation of epithelial plasticity and chemotherapy response in colorectal cancer

Article Title: Patient-derived models reveal LTBP2-linked collagen I niche that prime adaptive cell plasticity and tune chemoresponse in colorectal cancer

Article References: Sagadevan, S., Dalleywater, W., Balasubramanian, B., Okkelman, I. A., Martinez-Espuga, M., Norkin, M., Gall, L., Mendonca, T., Mukherjee, A., Wright, A. J., Dmitriev, R. I., Acheson, A. G., Huelsken, J., Mata, A., Pin, C., & Ordóñez-Morán, P. (2026). Patient-derived models reveal LTBP2-linked collagen I niche that prime adaptive cell plasticity and tune chemoresponse in colorectal cancer. Journal of Experimental & Clinical Cancer Research. https://doi.org/10.1186/s13046-026-03845-w

Image Credits: AI Generated

DOI: 10.1186/s13046-026-03845-w

Keywords: colorectal cancer, collagen I, extracellular matrix, LTBP2, TGF-beta, patient-derived organoids, epithelial-mesenchymal transition, cell plasticity, chemotherapy resistance, 5-fluorouracil, p38 MAPK, tumor microenvironment

The team focused on non-small cell lung cancer (NSCLC), the most common form of lung malignancy, and on bevacizumab, a monoclonal antibody that neutralizes vascular endothelial growth factor A (VEGFA), the master signal that tumors use to recruit new blood vessels. Bevacizumab does suppress neovascularization, but its benefit is frequently transient. The researchers set out to determine what the tumor does in response to this blockade, and the answer they uncovered is a classic example of biological compensation: the very act of cutting off the oxygen supply activates a survival program that helps the tumor adapt and evade the therapy.

Using human NSCLC cell systems, the investigators showed that inhibiting VEGFA paradoxically intensifies intratumoral hypoxia, the oxygen-starved state that develops when vessels fail to keep pace with tumor growth. Hypoxia is not merely a passive consequence of poor blood supply; it is a potent signaling condition. Under low oxygen, the transcription factor HIF1A is stabilized and accumulates in the nucleus, where it switches on a battery of genes that promote malignancy. In their experiments, VEGFA inhibition was consistently accompanied by an upregulation of HIF1A, and elevated HIF1A in turn drove measurable increases in tumor cell migration, epithelial-to-mesenchymal transition (the process by which stationary epithelial cells acquire the motile, invasive traits of mesenchymal cells), and resistance to cisplatin, a mainstay chemotherapy drug for lung cancer.

Perhaps the most consequential discovery concerns CD105, also known as Endoglin. The study found that HIF1A upregulates CD105, a hypoxia-responsive pro-angiogenic mediator expressed on proliferating endothelial cells. In practical terms, this means that when bevacizumab blocks VEGFA and the tumor becomes hypoxic, the resulting HIF1A surge pushes endothelial cells toward CD105-dependent vessel formation, an alternative angiogenic route that the antibody does not touch. The researchers describe this as a hypoxia-driven HIF1A-CD105 axis that sustains tumor aggressiveness and vascular adaptation despite continued VEGFA blockade. It is a molecular account of why anti-angiogenic therapy so often buys time rather than cures: the treatment itself creates the conditions for vascular escape.

Having identified the resistance circuit, the team went looking for a way to disable both of its nodes at once, and they found it in an unexpected place: the precursor of a naturally occurring microRNA. MicroRNAs are short regulatory RNA molecules that fine-tune gene expression by binding complementary sequences in target messenger RNAs and repressing their translation or stability. Most microRNAs are produced from hairpin-shaped precursors, and the canonical model treats one strand of the resulting duplex as the functional guide strand while the other, the passenger strand, is discarded as waste. The pre-miR-16-1 hairpin defies this simplification, and the new study demonstrates that both of its strands carry therapeutic information.

The guide strand, miR-16-5p, directly represses VEGFA, functionally recapitulating the anti-angiogenic action of bevacizumab but at the level of gene expression rather than protein neutralization. The passenger strand, miR-16-1-3p, performs an entirely different and complementary task: it suppresses HIF1A expression itself, preventing the hypoxia-induced malignant program from ever being switched on and, as a downstream consequence, limiting the upregulation of CD105. In other words, a single duplex derived from a physiological microRNA precursor contains, in its two strands, a coordinated attack on both the angiogenic engine and the adaptive hypoxic feedback that ordinarily undermines anti-angiogenic drugs.

The functional analyses underpinning this claim were systematic. When the researchers inhibited VEGFA alone, they observed the expected rise in HIF1A along with the associated malignant phenotypes: enhanced migration, mesenchymal-like morphological changes, and increased cisplatin resistance. When they co-expressed miR-16-1-3p, HIF1A levels fell and these adverse phenotypes were attenuated. This strand-by-strand dissection establishes causality rather than mere correlation: the passenger strand is not a passive byproduct of microRNA biogenesis but an active suppressor of the hypoxic response, and its inclusion is what converts a one-target intervention into a two-target one.

The decisive test came in vivo. Using the chick chorioallantoic membrane (CAM) xenograft model, a widely used platform in which human tumor cells are grafted onto the vascularized membrane of a chick embryo, the team compared single anti-angiogenic intervention with the dual regulatory approach. The results were striking. Dual regulation of VEGFA and HIF1A markedly reduced vascular density, tumor growth, and metastatic dissemination compared with blocking VEGFA alone. The reduction in metastatic burden is particularly noteworthy, because it suggests that suppressing the hypoxic response does more than improve vascular control; it also removes a key driver of the invasive and migratory behavior that allows cancer cells to seed distant sites.

The broader significance of the work lies in its reframing of anti-angiogenic resistance. Rather than treating resistance as an accident of tumor evolution, the study characterizes it as a predictable, pathway-level consequence of therapy: block VEGFA, induce hypoxia, stabilize HIF1A, upregulate CD105, and the tumor rebuilds its blood supply through a route the drug cannot reach. This logic suggests that the therapeutic window for anti-angiogenic treatment in NSCLC could be substantially widened by pairing VEGFA suppression with simultaneous HIF1A inhibition, and the pre-miR-16-1 duplex provides a proof of concept for how that pairing might be achieved with a single physiological molecule.

There are, of course, distance markers between a chick embryo membrane and the clinic. Delivering RNA duplexes reliably to tumor cells in human patients remains a formidable challenge, and the safety profile of simultaneously suppressing HIF1A, a transcription factor with normal roles in physiology, will require careful evaluation. Nevertheless, the study establishes a clear mechanistic framework and a candidate dual-regulatory agent grounded in the cell’s own RNA biology. By showing that the two strands of a single microRNA precursor can cooperate to strike both the VEGF pathway and the hypoxic feedback loop that rescues it, the researchers have turned a discarded passenger strand into a potential therapeutic partner, and they have given the field a concrete strategy for making anti-angiogenic therapy in lung cancer live up, at last, to its original promise.

Subject of Research: Dual targeting of VEGFA and HIF1A pathways by the pre-miR-16-1 microRNA duplex to overcome anti-angiogenic therapy resistance in non-small cell lung cancer

Article Title: Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer

Article References: Wang, Y., Xue, W., Malakhov, P. A., Smirnova, A. V., Pustovalova, M., Kuzmin, D. V., & Leonov, S. (2026). Harnessing the cooperative function of duplex from pre-miR-16 hairpin to simultaneously inhibit VEGF and hypoxia pathways in human non-small cell lung cancer. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03392-5

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03392-5

Keywords: non-small cell lung cancer, anti-angiogenic therapy, bevacizumab, VEGFA, HIF1A, hypoxia, CD105, Endoglin, miR-16, microRNA duplex, epithelial-mesenchymal transition, chemoresistance

To understand why this pathway has attracted such intense scrutiny, it helps to look at its molecular architecture. In its canonical form, NF-κB dimers—most commonly composed of the p65 (RelA) and p50 subunits—sit idle in the cytoplasm, tethered by inhibitory IκB proteins. When pro-inflammatory cytokines such as tumour necrosis factor alpha or interleukin-1 engage their receptors, a signalling cascade triggers the IκB kinase (IKK) complex, whose regulatory NEMO subunit assembles a ubiquitin-dependent signalosome. IKK then phosphorylates IκBα, marking it for proteasomal destruction and freeing NF-κB to enter the nucleus and switch on hundreds of target genes. The non-canonical arm works differently: NF-κB-inducing kinase (NIK) activates an IKKα-dependent process that processes the precursor p100 into p52, generating RelB/p52 dimers that control a distinct set of genes involved in lymphoid organogenesis, immune cell function and, crucially, tumour-microenvironment communication. The review emphasises that these two arms are not isolated modules but a single integrated system, with feedback loops, shared components such as the fourth IκB protein, and cross-regulation that shapes both the timing and the composition of the transcriptional response.

What makes NF-κB particularly treacherous in breast cancer is that its behaviour varies dramatically across molecular subtypes. The review systematically dissects luminal A, luminal B, HER2-enriched and basal-like or triple-negative disease, showing that the magnitude and biological consequences of NF-κB activation are anything but uniform. In hormone receptor-positive tumours, NF-κB engages in intimate crosstalk with the oestrogen receptor alpha. Landmark work cited in the review demonstrated that an IKKα-dependent transcriptional complex is required for oestrogen receptor-mediated gene activation, meaning that the inflammatory pathway is not merely a parallel route to malignancy but is physically embedded in the machinery that oestrogen-responsive tumours depend upon. This entanglement helps explain why NF-κB activity is repeatedly implicated in endocrine therapy resistance: as tumours evolve under the selective pressure of anti-oestrogen drugs, they appear to lean increasingly on inflammatory signalling to maintain survival programmes that the blocked receptor can no longer fully provide.

In HER2-positive disease, the picture shifts toward cooperation with the HER2-PI3K-AKT axis, one of the most consequential growth-factor pathways in this aggressive subtype. Constitutive activation of PI3K-AKT signalling can potentiate NF-κB-dependent transcription, reinforcing anti-apoptotic gene expression and supporting the survival of tumour cells exposed to HER2-targeted agents. The review also highlights experimental evidence that blocking NF-κB can enhance the responsiveness of mammary tumours to JAK inhibitors, suggesting that inflammatory and cytokine signalling pathways converge in ways that single-agent approaches fail to fully exploit. For triple-negative breast cancer—the subtype with the fewest targeted options—NF-κB assumes an even more central role. Studies using small inhibitory RNAs in oestrogen receptor-negative cell lines showed that suppressing the pathway impairs proliferation and survival, while IKK inhibition with compounds such as BMS-345541 has been reported to suppress breast tumorigenesis and metastasis by targeting GD2-positive cancer stem cell populations, the self-renewing cells widely believed to seed relapse and metastatic spread.

Perhaps the most clinically resonant section of the review concerns epithelial-mesenchymal transition, the cellular reprogramming that allows epithelial tumour cells to acquire motility, invasiveness and stem-like properties. NF-κB has been shown to regulate the expression of key EMT genes in breast cancer cells, effectively serving as a transcriptional gatekeeper for the plasticity that underpins metastasis. This connects directly to the inflammatory cytokine network: interleukin-1 signalling through NF-κB has been shown to be required for tumour invasiveness and angiogenesis in experimental models, and endogenous production of interleukin-1 beta by breast cancer cells has been demonstrated to drive metastasis and colonisation of the bone microenvironment in patient-derived systems. In other words, NF-κB does not merely respond to inflammation—it helps tumour cells manufacture their own inflammatory niche, a self-reinforcing loop that promotes dissemination to bone, the most common site of breast cancer metastasis.

The tumour microenvironment adds another layer of complexity. The review devotes substantial attention to macrophage heterogeneity, describing how tumour-associated macrophages can be co-opted by cancer cells to support growth and immune evasion. Recent work on an unconventional p65/p52 NF-κB module in breast tumour-associated macrophages suggests that these infiltrating immune cells use hybrid canonical-non-canonical signalling to regulate genes that shape the microenvironment in the tumour’s favour. Structural biology is beginning to illuminate how different NF-κB dimer compositions read DNA and activate transcription, with high-resolution studies of p52 homodimer-DNA complexes and NMR analyses of NF-κB-DNA interactions rationalising why specific dimer combinations produce distinct transcriptional outcomes. This structural and mechanistic granularity matters therapeutically: if different dimers control different gene programmes in different cellular compartments, then blunt pathway inhibition risks suppressing beneficial immune functions while sparing the tumour-promoting activities clinicians most want to eliminate.

Genotoxic stress introduces yet another dimension. Chemotherapy and radiotherapy work in part by damaging DNA, yet the review describes how the LUBAC ubiquitin ligase complex promotes linear ubiquitination of NEMO in response to genotoxic stress, activating NF-κB precisely when tumour cells are under attack. This damage-induced NF-κB activity can function as a survival shield, upregulating anti-apoptotic genes and helping cells repair or tolerate the damage inflicted by treatment. Consistent with this, proteasome inhibition with bortezomib has been shown to restore apoptotic factors and sensitise breast cancer cells to docetaxel in preclinical models, and clinical trials have tested bortezomib in combination with capecitabine in metastatic disease and with fulvestrant in hormone receptor-positive tumours resistant to aromatase inhibitors. A related strategy exploits SMAC mimetics, which synergise with endocrine therapy to potentiate antigen presentation and tumour regression in hormone receptor-positive breast cancer, in part by disabling NF-κB-dependent survival pathways.

Therapeutically, the review maps out a spectrum of intervention points, each with distinct trade-offs. Upstream inhibition can target receptor-level signals such as RANK/RANKL, which has attracted attention as a potential prevention target in BRCA1-mutation carriers, with a systematic review and meta-analysis now assessing the prognostic value of RANK signalling across breast cancer populations. Proteasome blockade offers a broad but toxic approach; selective NIK inhibitors are advancing as a more precise way to disable the non-canonical arm; and IKK inhibitors aim at the convergence point of both pathways. The authors also highlight emerging precision-delivery strategies and targeted-degradation concepts, including approaches that could eliminate specific NF-κB subunits rather than merely silencing their activity. Yet the review is notably candid about the translational gap: clinical data remain sparse relative to an enormous preclinical literature, and indiscriminate NF-κB inhibition carries real risks, given the pathway’s essential roles in immunity and inflammation.

The overarching message is one of disciplined optimism. NF-κB is neither a universal villain nor an untouchable guardian; it is a context-dependent network whose contribution to breast cancer depends on subtype, dimer composition, cellular compartment and the surrounding microenvironment. The review proposes a framework for subtype- and context-selective targeting, anchored in biomarker-driven patient stratification rather than blanket suppression. If that framework can be validated, the inflammatory switch that breast cancers exploit to survive, spread and resist treatment may finally become the vulnerability that clinicians have been searching for.

Subject of Research: NF-κB signalling mechanisms, crosstalk and therapeutic targeting in breast cancer

Article Title: Nuclear factor κB signalling in breast cancer: mechanisms, crosstalk and therapeutic targeting

Article References: Muthiah, B., Santha Moorthi Rajah, R. R., Kumar, A. S., Srikesavan, S., Chandrasekaran, V. N., & Priya, K. (2026). Nuclear factor κB signalling in breast cancer: mechanisms, crosstalk and therapeutic targeting. Molecular Biology Reports, 53(1), Article 1687. https://doi.org/10.1007/s11033-026-12871-y

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12871-y

Keywords: NF-κB, breast cancer, canonical pathway, non-canonical pathway, IKK, NIK, HER2, triple-negative breast cancer, tumour microenvironment, therapy resistance, EMT, RANK/RANKL

The research, led by Thoria Donia and Mohamed Hessien along with colleagues at Tanta University and collaborating Egyptian institutes, focused on two cell lines that loom large in cancer biology. HepG2 cells, derived from a human hepatocellular carcinoma, represent the most common form of liver cancer and a leading cause of cancer death worldwide. MDA-MB-231 cells, meanwhile, are a notoriously aggressive model of triple-negative breast cancer, the subtype that resists hormone therapy and targeted drugs alike. The team measured how much chlorpromazine was needed to kill half of the cells in each culture, a standard benchmark known as the IC50. When mdivi-1 was added alongside the antipsychotic, that lethal dose dropped in both cell lines, with the liver cancer cells proving noticeably more responsive than their breast cancer counterparts.

That synergy is not accidental, and the study’s technical work explains why it happens. Mdivi-1 was originally identified in 2008 as a small molecule that blocks dynamin-related protein 1, or Drp1, the molecular engine that pinches mitochondria in two during cell division of these organelles. Cancer cells are famously dependent on finely tuned mitochondrial dynamics, the constant cycling of fusion and fission that keeps their powerhouses distributed, their metabolism flexible, and their survival machinery primed. By jamming the fission machinery, mdivi-1 throws that balance into disarray. Chlorpromazine, for its part, has long been known to disrupt clathrin-mediated endocytosis, the cellular trafficking route that tumors exploit for growth signaling, and earlier studies have shown it can trigger cell cycle arrest and autophagy in cancers ranging from glioblastoma to colorectal tumors.

To probe what the combination was actually doing inside the cells, the researchers deployed a battery of assays that read out the hallmarks of dying and migrating cancer cells. Annexin V and propidium iodide staining, which flags the flipping of membrane phospholipids that marks early apoptosis, revealed a surge in programmed cell death under the dual treatment. Acridine orange and ethidium bromide, together with DAPI staining, exposed the nuclear signature of apoptosis: chromatin condensing into dense, fragmented clumps as the genome was dismantled. The combination also compromised cell membrane integrity, a sign that the cells were losing the structural coherence needed to survive. In clonogenic assays, which test whether single cells can found new colonies over days to weeks, the treated cultures produced far fewer colonies, indicating that the damage was not merely a transient shock but a lasting blow to reproductive capacity.

Migration, the behavior that lets tumors seed metastases throughout the body, was similarly throttled. In wound-healing assays, where a scratch is made across a confluent cell layer and the researchers watch how quickly cells crawl in to close the gap, the combination-treated cells moved sluggishly compared with controls. Behind that physical slowdown lay a molecular shift in epithelial-mesenchymal transition, the developmental program that cancer cells hijack to become mobile and invasive. The team found that the dual treatment downregulated the expression of vimentin and DDR2, two mesenchymal markers that signal a cell’s conversion into the migratory, invasive state. Suppressing this program is a major therapeutic goal in oncology, because mesenchymal tumor cells are typically the ones that break away, circulate, and establish deadly secondary tumors.

The mitochondrial story proved to be the most intricate thread of the study. On its own, mdivi-1 upregulated the expression of the fusion genes MFN1, MFN2, and OPA1, which encode the proteins that merge mitochondria and preserve their functional network. But when chlorpromazine entered the picture, the picture changed: the combined treatment dysregulated both the fusion and the fission gene sets, throwing the entire dynamical system out of balance. This matters because tumor cells rely on a specific rhythm of mitochondrial remodeling to support their abnormal metabolism and to evade apoptosis. Disrupting both sides of the fusion-fission equilibrium at once appears to deprive the cells of the flexibility they need to adapt, compounding the stress imposed by chlorpromazine itself.

Oxidative stress emerged as the engine that converts that mitochondrial chaos into cell death. Using 2′,7′-dichlorodihydrofluorescein diacetate staining, a fluorescent probe that lights up in the presence of reactive oxygen species, the researchers documented an overproduction of cellular ROS in the treated cells. At the same time, the cells’ antioxidant capacity was depleted, and the expression of Nrf2, the master transcription factor that orchestrates the cellular antioxidant response, was downregulated. Nrf2 is a double-edged sword in cancer: many tumors crank it up to neutralize the oxidative byproducts of their runaway metabolism and to resist chemotherapy. By suppressing Nrf2 while simultaneously flooding the cells with ROS, the drug combination stripped cancer cells of both the insult and the defense, leaving them with no route back to equilibrium except apoptosis.

The broader context makes the result more than a laboratory curiosity. Chlorpromazine belongs to a growing list of central nervous system drugs being reexamined as anticancer agents, a strategy that appeals to researchers because these compounds have decades of clinical safety data, known pharmacokinetics, and low manufacturing costs. Recent studies have shown phenothiazines can suppress proliferation in leukemic cells while sparing normal lymphocytes, overcome temozolomide resistance in glioblastoma by interfering with DNA repair pathways, and suppress the YAP signaling axis that drives stemness and drug resistance in breast cancer. Chlorpromazine has also been shown to induce G2/M cell cycle arrest in colorectal and oral cancer cells. Meanwhile, mdivi-1 has independently attracted attention for sensitizing cancer cells to cisplatin and paclitaxel and for suppressing oxidative metabolism in tumors, making the two drugs natural partners in a combination strategy.

Cautions remain before any of this reaches patients. The work was conducted entirely in cell culture, and the gap between a dish of HepG2 cells and a living tumor is wide, encompassing drug delivery, metabolism, immune interactions, and toxicity that no in vitro system can fully model. Chlorpromazine itself carries known liabilities, including hepatotoxicity under inflammatory conditions and extrapyramidal neurological side effects at antipsychotic doses, and the study’s authors and prior literature alike note that safety profiling would be essential. The researchers also point to ongoing efforts to design chlorpromazine derivatives that retain anticancer activity while shedding the neurological side effects, an approach that could yield cleaner candidates. Still, the convergence of a repurposed psychiatric drug with a mitochondrial dynamics inhibitor offers a mechanistically coherent blueprint: attack the trafficking, the power grid, and the antioxidant shield of a tumor cell all at once.

What makes the study resonate beyond its immediate findings is the way it reframes an old drug through a modern lens. Mitochondrial dynamics has moved from a niche organelle-biology topic to a recognized axis of cancer vulnerability, and the Tanta team’s data show that a fission inhibitor can convert a moderately cytotoxic antipsychotic into a substantially more potent anticancer combination. The work was supported by Egypt’s Academy of Scientific Research and Technology and the Science and Technology Development Fund, and the authors report no competing interests. For now, the combination lives in the realm of preclinical promise, but it strengthens the case for clinical exploration of phenothiazine-based regimens, particularly for liver and triple-negative breast cancers where treatment options remain painfully limited. If subsequent animal and human studies bear out the synergy, a drug that has treated the mind since the Eisenhower era may yet earn a second career treating the body.

Subject of Research: Repurposing chlorpromazine combined with the mitochondrial fission inhibitor mdivi-1 as an anticancer strategy in liver and breast cancer cell lines

Article Title: Mdivi-1 augments chlorpromazine’s anticancer effect via modulation of mitochondrial dynamics, hallmarks of cancer-related cellular behavior, and oxidative stress

Article References: Donia, T., Ismail, D. F., Alkafaas, S. S., Adly, E., Tabll, A. A., & Hessien, M. (2026). Mdivi-1 augments chlorpromazine’s anticancer effect via modulation of mitochondrial dynamics, hallmarks of cancer-related cellular behavior, and oxidative stress. Medical Oncology, 43(11), Article 325. https://doi.org/10.1007/s12032-026-03364-w

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03364-w

Keywords: chlorpromazine, mdivi-1, mitochondrial dynamics, drug repurposing, HepG2, MDA-MB-231, apoptosis, oxidative stress, Nrf2, epithelial-mesenchymal transition, mitochondrial fission, Medical Oncology

Steady states are the fixed points of a network’s dynamics, the configurations of gene activity that, once reached, persist indefinitely. In the language of cell biology, these steady states are interpreted as cellular phenotypes, the distinct identities a cell can adopt. A stem cell deciding between self-renewal and differentiation, an immune cell settling into an activated or exhausted state, or a cancer cell sliding into an invasive mode all correspond, in this framework, to different attractors of the underlying regulatory circuitry. The first step in understanding any network’s dynamics is therefore describing the full collection of steady states it can support under different conditions. But there is a catch: for any given gene regulatory network, there are usually many possible Boolean models consistent with its known interactions, and different models can disagree about which steady states exist.

The research team confronted this ambiguity head-on. Rather than picking a single Boolean model and analyzing it, they considered the collection of all monotone Boolean function models compatible with a given gene regulatory network. Monotone means that each regulatory interaction has a consistent sign: an activator never becomes an inhibitor and vice versa, which matches the biological reality of signed interactions in gene networks. Within this vast family of compatible models, the authors asked a deceptively simple question: which steady states are supported by most of the models? A steady state endorsed by nearly every compatible model is far more likely to reflect genuine cellular behavior than one that appears in only a handful of exotic parameterizations.

The key insight that unlocks the problem comes from an unexpected corner of mathematics: the algebraic structure of the lattices of monotone Boolean functions. The authors proved that the set of monotone Boolean models supporting a given equilibrium can be decomposed as a product of prime ideals and prime filters of these lattices. In practical terms, this structural theorem converts a seemingly intractable counting problem, enumerating and weighing enormous numbers of Boolean models, into an explicit computation. Instead of simulating thousands of network variants and tallying outcomes, researchers can now characterize, with precision, exactly which models support a given fixed point and how large that supporting set is relative to the whole space of compatible models.

The theorem delivers its most striking payoff for balanced networks, a class of regulatory networks whose signed interaction structure satisfies a consistency condition around every feedback loop. In such networks, the authors found an explicit hierarchy in the prevalence of individual steady states, as well as in the prevalence of bistability and multistability. Bistability refers to a network’s capacity to settle into two alternative stable states, a property widely believed to underlie biological switch-like decisions, while multistability extends this to three or more coexisting stable outcomes. The new results mean that for balanced networks, one can rank steady states and multistable configurations by how commonly they arise across all compatible models, without ever committing to a specific parameter choice.

This hierarchy has immediate biological consequences, because it turns model uncertainty from a nuisance into a source of information. When most models compatible with a network agree that a particular pair of states is bistable, that bistability is robust to the unknown details of the regulatory functions. Conversely, a steady state that only rare models support can be flagged as fragile, a prediction that experiments could test by perturbing the network and observing whether the state appears. The framework thus provides a principled way to distinguish between the behaviors a network reliably produces and the artifacts of particular modeling assumptions, a distinction that has often been blurred in the computational biology literature.

To demonstrate the power of the approach, the authors applied it to a network of direct clinical relevance: the epithelial-mesenchymal transition network, a regulatory circuit implicated in cancer metastasis. During this transition, epithelial cells, which are typically stationary and tightly bound to their neighbors, lose their adhesions and acquire the motile, invasive characteristics of mesenchymal cells. The process is a hallmark of cancer progression, enabling tumor cells to detach from the primary tumor, migrate through surrounding tissue, and seed metastases at distant sites. Understanding which states this network can stably maintain, and how easily it flips between them, is therefore a central goal of computational oncology.

The analysis of the EMT network produced an elegant result. Across all monotone Boolean models compatible with the network’s structure, the most common equilibria correspond precisely to the fully epithelial state and the fully mesenchymal state, the two biologically recognized extremes of the spectrum. Moreover, the bistability between these two states emerged as the most common bistability among all network-compatible monotone Boolean models. In other words, the mathematical hierarchy of model prevalence aligns with experimental observations of the transition: cells genuinely occupy these two principal phenotypes, and the switch between them is the network’s dominant binary decision. The agreement between the abstract counting of models and the concrete biology of metastasis suggests that the structure of a gene network alone encodes a surprising amount of its functional behavior.

Why should this alignment exist? One interpretation is that evolution has wired regulatory networks so that their most robust dynamical behaviors, those supported by the widest range of mechanistic implementations, are exactly the behaviors the organism needs. A phenotype that survives variation in the fine details of gene regulation is a phenotype that can be reliably produced across genetic backgrounds and environmental conditions. The prevalence hierarchy computed by the new method can be read as a measure of this robustness, offering evolutionary theorists a quantitative handle on why certain cellular decisions, like the epithelial-mesenchymal switch, appear so consistently across tissues and species while others remain rare and context-dependent.

The broader implications reach beyond cancer biology. Because the method applies to any monotone gene regulatory network, and yields explicit results for balanced networks, it provides a general toolkit for interrogating the multistability of developmental circuits, immune regulatory modules, and synthetic gene networks designed in the laboratory. Engineers building synthetic circuits could use the hierarchy to choose wiring diagrams whose desired states are maximally prevalent across models, maximizing the odds that the circuit behaves as intended despite uncertainty in its molecular details. For experimentalists, the framework generates testable predictions about which phenotypes should be common, which should be rare, and which transitions should be easy or hard to trigger. What began as an abstract question about Boolean functions and their ideals has matured into a practical lens on one of biology’s deepest puzzles: how the same wiring diagram can give rise to the reliable, switch-like decisions that cells make every day.

Subject of Research: Characterization of steady states and multistability in monotone Boolean models of gene regulatory networks

Article Title: Characterization of monotone Boolean models supporting fixed points and multistability in balanced networks

Article References: Adigwe, S., BV, H., Jolly, M. K., & Gedeon, T. (2026). Characterization of monotone Boolean models supporting fixed points and multistability in balanced networks. PLOS Complex Systems, 3(5), e0000103. https://doi.org/10.1371/journal.pcsy.0000103

Image Credits: AI Generated

DOI: 10.1371/journal.pcsy.0000103

Keywords: gene regulatory networks, Boolean models, steady states, multistability, bistability, balanced networks, monotone functions, epithelial-mesenchymal transition, cancer metastasis, systems biology, fixed points, cellular phenotypes

Snail2, known in the literature as SNAI2 or by its older name Slug, belongs to the Snail superfamily of C2H2 zinc-finger transcription factors. These proteins bind DNA through characteristic finger-like zinc-coordinated loops and act as molecular switches, repressing or activating entire gene programs. Within this family, Snail2 has earned a reputation as a master regulator of epithelial-mesenchymal transition, the process by which tightly packed epithelial cells loosen their junctions, remodel their cytoskeletons and acquire the motile behavior of mesenchymal cells. What distinguishes Snail2 from its relatives, the review argues, is that it does not typically drive the complete version of this transition. Rather, it promotes a partial EMT, a hybrid state in which cells retain epithelial traits such as cell-cell adhesion while simultaneously gaining mesenchymal motility.

That hybrid state is far from a biological curiosity. In tumors, cells caught between epithelial and mesenchymal identities appear to be the most effective colonizers, capable of detaching, traveling through circulation and then re-establishing themselves at distant sites. Because partial EMT is reversible, cells that complete the journey can revert to a proliferative epithelial phenotype and seed new lesions. The review positions Snail2 as a distinctive driver of this plasticity, contrasting it with other EMT transcription factors that push cells all the way to a fully mesenchymal fate. Understanding precisely how Snail2 calibrates this in-between state, the authors note, remains one of the field’s most pressing unanswered questions.

The regulatory machinery surrounding Snail2 is correspondingly elaborate. The review describes a multi-layered network that controls the protein at every stage of its life cycle. At the transcriptional level, numerous signaling pathways converge on the SNAI2 promoter to determine how much messenger RNA is produced. Post-transcriptional mechanisms, particularly microRNAs and RNA-binding proteins, then determine the stability and translation efficiency of that transcript. Translational control adds a further gate, and post-translational modifications, including phosphorylation, ubiquitination and other chemical tags, govern the stability, localization and activity of the protein itself. This layered architecture means that Snail2 activity can be tuned finely and rapidly, which is exactly what a system requiring reversible cell-state transitions demands.

In normal development, this tunability is put to spectacular use. The review devotes substantial attention to the neural crest, a transient embryonic cell population that arises at the border of the neural plate and gives rise to an astonishing range of tissues, from craniofacial bone and cartilage to neurons of the peripheral nervous system and pigment cells. Snail2 is critical for neural crest formation and migration, endowing these cells with the motility they need to travel long distances across the embryo. Without properly regulated Snail2, neural crest cells fail to delaminate and migrate correctly, with consequences that echo through craniofacial and nervous system development.

The developmental portfolio of Snail2 extends well beyond the neural crest. The review catalogs its involvement in gland development, where branching epithelial structures depend on controlled cell rearrangements; in vascular development, where endothelial cells must remodel into functional networks; and in cardiac valve development, where an EMT-like process generates the cellular cushion tissue of the heart. Snail2 also participates in chondrogenesis and skeletal development, guiding cartilage formation and bone patterning. In each of these contexts, the same underlying logic applies: Snail2 temporarily loosens epithelial constraints or activates migratory programs, then steps back as cells settle into their final differentiated identities. Development, in this view, is a choreography of controlled plasticity, and Snail2 is one of its principal choreographers.

In disease, that same choreography is co-opted to destructive ends. The review details how Snail2 drives cancer progression through epigenetic reprogramming, recruiting repressive complexes to silence epithelial genes such as those encoding cell adhesion molecules, while activating mesenchymal and stemness-associated programs. The result is a tumor cell equipped for invasion, metastasis, self-renewal and resistance to chemotherapy. Chemoresistance is a particularly consequential outcome, because cells in a partial EMT state can survive cytotoxic insults that kill their more differentiated neighbors, then repopulate the tumor once treatment ends. Snail2’s role in maintaining this resilient subpopulation makes it an attractive target for therapies aimed not just at shrinking tumors but at eliminating the cells responsible for relapse.

The pathological reach of Snail2 is not confined to cancer. The review links it to cardiovascular, respiratory, renal and gynecological disorders, all unified by a common mechanism: EMT-mediated tissue remodeling and chronic inflammation. In fibrotic diseases of the lung and kidney, for example, epithelial cells that undergo partial EMT contribute to the accumulation of matrix-producing cells that progressively stiffen and destroy organ function. In vascular disease, endothelial cells that lose their identity through similar transitions contribute to plaque instability and dysfunction. In gynecological tissues, aberrant EMT-like programs underlie pathological remodeling processes. Across all of these systems, Snail2 sits at a regulatory node where inflammatory signals and tissue injury converge on cell-state change.

Despite the breadth of what is known, the review is candid about the gaps. The molecular determinants that specify partial rather than complete EMT remain poorly defined, as do the reasons why Snail2 performs different functions in different cellular contexts. Translational control of Snail2, the mechanisms that determine how efficiently its messenger RNA becomes protein, is another underexplored layer. Perhaps most intriguingly, the authors highlight Snail2’s emerging role in shaping the tumor immune microenvironment, suggesting that the transcription factor may influence not only cancer cells themselves but also how immune cells perceive and respond to them. Resolving these questions, the review argues, will require integrating approaches spanning chromatin biology, single-cell analysis and immunology.

The therapeutic implications are considerable but cautionary. Directly inhibiting a transcription factor has historically been difficult, and Snail2’s essential roles in development and tissue repair mean that systemic suppression carries risks. The more realistic near-term strategy, the review suggests, is to target the regulatory network around Snail2, the kinases, ubiquitin ligases, microRNAs and chromatin modifiers that keep it in check, or to exploit the vulnerabilities of the hybrid epithelial-mesenchymal state it maintains. As metastasis remains the leading cause of cancer death, a deeper mechanistic grasp of the protein that governs cellular plasticity could reshape how clinicians think about preventing spread rather than merely treating established tumors. For a factor once studied mainly in embryology textbooks, Snail2 has become a focal point where developmental biology and cancer medicine converge.

Subject of Research: The roles and regulatory mechanisms of the transcription factor Snail2 in epithelial-mesenchymal transition, development and disease

Article Title: Snail2: roles and regulatory mechanisms in development and disease

Article References: Chen, Y., He, Z., Jiao, Y., Hao, H., Cui, Z., Zhao, K., Cong, X., & Hu, Y. (2026). Snail2: roles and regulatory mechanisms in development and disease. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03351-0

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03351-0

Keywords: Snail2, SNAI2, epithelial-mesenchymal transition, partial EMT, transcription factor, neural crest, metastasis, cancer, chemoresistance, cell plasticity, epigenetic reprogramming, tumor microenvironment

The central concept is the gut-pancreas axis, a bidirectional communication network linking the intestinal lumen, the intestinal barrier, the biliary and pancreatic ducts, and the pancreatic tissue itself. In a healthy state, the gut microbiota helps maintain intestinal homeostasis, supports the integrity of the epithelial barrier and contributes to endocrine signaling through gut hormones and enteroendocrine cells. When dysbiosis disrupts this equilibrium, the review proposes that damage proceeds along two broad routes. The first involves direct cell damage driven by microbial products and toxins that cross a compromised barrier. The second involves the generation of a distinctive set of metabolic products, including short-chain fatty acids, bile acid derivatives and other bacterial metabolites, which activate diverse signaling pathways and cytokine networks. The endpoint of both routes is systemic inflammation, a chronic, low-grade inflammatory state that bathes distant organs, including the pancreas, in immune signaling molecules.

For type 2 diabetes, the review identifies inflammatory signaling as the key mechanism by which dysbiosis impairs glucose control. Chronic inflammation predominantly disrupts the IRS-1/PI3K/AKT signaling cascade, the intracellular pathway through which the insulin receptor transmits its message. When this pathway is blunted, cells absorb glucose less efficiently, a hallmark of insulin resistance. At the same time, inflammatory stress contributes to the malfunction of pancreatic beta cells, the insulin-producing cells of the islets, creating a vicious cycle in which rising blood glucose and failing insulin action reinforce one another. The review also highlights the phenomenon of metabolic endotoxemia, in which bacterial lipopolysaccharide translocating from a leaky gut into the circulation initiates obesity and insulin resistance, a mechanism supported by experimental studies cited in the article.

The evidence linking specific microbial changes to diabetes is substantial. Large metagenome-wide association studies have shown that individuals with type 2 diabetes carry a distinct gut microbial signature, and long-term instability of the intestinal microbiome has been associated with low microbial diversity, diabetes and impaired exocrine pancreatic function. Experimental work in mice has demonstrated that a dysbiotic microbiota typical of type 2 diabetes can induce resistance to GLP-1, an incretin hormone central to glucose regulation, through enteric nitric oxide-dependent mechanisms along the gut-brain axis. Intriguingly, some of the most widely used diabetes drugs appear to act partly through the microbiome: metformin has been shown to alter the gut microbiome of treatment-naive patients in ways that contribute to its therapeutic effects, and GLP-1 receptor agonists appear to engage in a bidirectional relationship with gut microbes.

Pancreatic cancer, one of the deadliest malignancies, emerges in the review as another disease in which microbial dysbiosis may act as a pathogenic driver. In pancreatic ductal adenocarcinoma, dysbiosis-associated inflammatory signaling is proposed to stimulate tumor growth through three converging mechanisms: activation of oncogenic pathways, promotion of immune evasion, and induction of epithelial-mesenchymal transition, the cellular program by which epithelial cells acquire invasive, migratory properties. Bacterial metabolites can additionally cause DNA mutations and perturb the signaling pathways of cancer cells, adding a direct genotoxic dimension to the inflammatory one. Studies of patients with pancreatic cancer have documented dysbiotic gut microbiota that form correlation networks with the oral microbiota and with prognostic factors, and microbial dysbiosis together with altered polyamine metabolism has been proposed as a predictive marker for early detection of the disease.

Perhaps the most striking findings concern the tumor microbiome itself. Research cited in the review shows that the pancreatic cancer microbiome promotes oncogenesis by inducing innate and adaptive immune suppression, effectively turning resident microbes into allies of the tumor. The fungal community, or mycobiome, has also been implicated: fungal populations can promote pancreatic oncogenesis through activation of the mannose-binding lectin pathway, and fungi drive interleukin-33 secretion and type 2 immunity within the tumor microenvironment. The diversity and composition of the tumor microbiome, in turn, influence patient outcomes, suggesting that microbial profiling could eventually inform prognosis and treatment selection. These observations extend the gut-pancreas axis concept from a metabolic framework to an immunological one, in which microbes shape the tumor’s ability to hide from immune attack.

The review integrates these threads into a unified microbiome-driven inflammatory-metabolic paradigm. In this framework, diabetes and pancreatic cancer are not merely coincident diseases in the same patients, as epidemiology has long suggested, but are connected by shared upstream mechanisms rooted in the gut. Hyperinsulinemia itself is recognized as a cancer-promoting condition, and inflammation, described in the broader literature as metaflammation, links immunometabolic dysfunction to malignant transformation. Dysbiosis-driven signaling cascades involving interleukin-1 beta and NOX4-dependent pathways have been shown experimentally to regulate both diabetes and cancer progression, providing a concrete molecular bridge between the two conditions. The same leaky barrier, the same endotoxemia and the same cytokine storm that erode insulin sensitivity can, over time, foster an environment permissive to pancreatic tumor development.

This mechanistic convergence points toward a therapeutic frontier: targeted modification of the gut microbiome. The review surveys a range of interventions, from probiotics and prebiotics to synbiotics and fecal microbiota transplantation. Supplementation with the beneficial bacterium Akkermansia muciniphila has shown proof-of-concept benefits in overweight and obese volunteers, while the anti-inflammatory commensal Faecalibacterium prausnitzii has been identified through studies of inflammatory disease. Fecal microbiota transplantation has been shown to increase insulin sensitivity in individuals with metabolic syndrome and to ameliorate type 2 diabetes in animal models through metabolic remodeling of the gut microbiota. In the oncology setting, probiotic Lactobacillus strains have shown synergistic tumor-growth-inhibitory effects in transgenic mouse models of pancreatic cancer treated with gemcitabine, and researchers have explored counteracting the dysbiosis induced by chemotherapy regimens such as gemcitabine plus nab-paclitaxel. Postbiotics, the bioactive metabolites produced by microbes, are being investigated as sensitizers of cancer cells to immune checkpoint inhibitors, and microbiota-based nanotherapies represent an emerging delivery strategy.

Diet is the most accessible lever on the axis. Dietary fiber, polyphenols, omega-3 fatty acids and Mediterranean-style eating patterns all modulate gut microbiota composition and metabolite production, and fiber-derived short-chain fatty acids are among the best-characterized beneficial bacterial metabolites in human physiology. The review also emphasizes caution, noting that host variables can confound microbiota studies of human disease, that establishing causality remains a methodological challenge, and that the field has issued consensus statements on the rigorous use of preclinical models and standardized analytical practices. Personalized nutrition, which predicts individual glycemic responses based on microbiome and host features, illustrates how far the field has moved toward precision applications.

The significance of this synthesis lies in its reframing of two major diseases as potentially preventable through the same biological interface. If dysbiosis is a genuine pathogenic driver rather than a passive bystander, then restoring a healthy gut ecosystem could simultaneously reduce diabetes risk and lower the incidence or improve the treatment of pancreatic cancer, a disease for which few modifiable risk factors are currently actionable. The author argues that a realistic and in-depth understanding of gut-pancreas mechanisms could yield new techniques for targeted microbiome modification in both prevention and management. Much work remains, from causal validation in humans to standardized interventions and clinical trials, but the direction is clear: the road to the pancreas, and perhaps to better outcomes in two devastating diseases, may run directly through the gut.

Subject of Research: The role of gut microbial dysbiosis in the development of type 2 diabetes and pancreatic cancer via the gut-pancreas axis

Article Title: The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer

Article References: The gut-pancreas axis: microbial dysbiosis as a pathogenic driver of diabetes and pancreatic cancer. (n.d.). https://doi.org/10.1007/s12032-026-03421-4

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03421-4

Keywords: gut microbiome, dysbiosis, gut-pancreas axis, type 2 diabetes, pancreatic cancer, insulin resistance, inflammation, microbial metabolites, IRS-1/PI3K/AKT signaling, epithelial-mesenchymal transition, probiotics, fecal microbiota transplantation